Debrisoquine (BioDeep_00000001325)

 

Secondary id: BioDeep_00000408942

human metabolite Endogenous blood metabolite Chemicals and Drugs natural product


代谢物信息卡片


1,2,3,4-tetrahydroisoquinoline-2-carboximidamide

化学式: C10H13N3 (175.1109)
中文名称: 异喹胍, 去溴喹
谱图信息: 最多检出来源 Homo sapiens(blood) 38.21%

分子结构信息

SMILES: c1ccc2CN(CCc2c1)C(=N)N
InChI: InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)

描述信息

Debrisoquine is an adrenergic neuron-blocking drug. Genetic and environmental factors are determinants of the interindividual and interethnic variability in drug metabolism. Thus, interethnic differences in debrisoquine hydroxylation polymorphism (Cytochrome p450, subfamily IID, polypeptide 6, CYP2D6) might be partly responsible for the variation in haloperidol disposition between races. The influence of tobacco, ethanol, caffeine, gender, and oral contraceptive use on the debrisoquine metabolic ratio (MR) has been analyzed in panels of healthy volunteers. About 5-10\\% of European white population has a genetically determinant defect of the CYP2D6, one of the enzymes of cytochrome P-450. This defect leads to the impaired metabolism of many drugs including various psychopharmacological agents. The measurement of the hydroxylation of debrisoquine is a laboratory test which allows identifying such an individual. Patients who show an impaired hydroxylation of debrisoquine usually demonstrate severe side effects and poor outcome of psychopharmacotherapy. In practice, knowledge of a patients debrisoquine metabolic phenotype is an advantage when prescribing tricyclic antidepressants and neuroleptics, as the drug concentration will be considerably higher in slow metabolisers than in the average patient. (PMID: 8839686, 1738265, 7878155) [HMDB]
Debrisoquine is an adrenergic neuron-blocking drug. Genetic and environmental factors are determinants of the interindividual and interethnic variability in drug metabolism. Thus, interethnic differences in debrisoquine hydroxylation polymorphism (Cytochrome p450, subfamily IID, polypeptide 6, CYP2D6) might be partly responsible for the variation in haloperidol disposition between races. The influence of tobacco, ethanol, caffeine, gender, and oral contraceptive use on the debrisoquine metabolic ratio (MR) has been analyzed in panels of healthy volunteers. About 5-10\\% of European white population has a genetically determinant defect of the CYP2D6, one of the enzymes of cytochrome P-450. This defect leads to the impaired metabolism of many drugs including various psychopharmacological agents. The measurement of the hydroxylation of debrisoquine is a laboratory test which allows identifying such an individual. Patients who show an impaired hydroxylation of debrisoquine usually demonstrate severe side effects and poor outcome of psychopharmacotherapy. In practice, knowledge of a patients debrisoquine metabolic phenotype is an advantage when prescribing tricyclic antidepressants and neuroleptics, as the drug concentration will be considerably higher in slow metabolisers than in the average patient. (PMID: 8839686, 1738265, 7878155).
C - Cardiovascular system > C02 - Antihypertensives > C02C - Antiadrenergic agents, peripherally acting > C02CC - Guanidine derivatives
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
COVID info from COVID-19 Disease Map
ATC code: C02CC04
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS

同义名列表

14 个代谢物同义名

1,2,3,4-tetrahydroisoquinoline-2-carboximidamide; 3,4-dihydro-2(1H)-Isoquinolinecarboximidamide; 3,4-DIHYDROISOQUINOLINE-2(1H)-CARBOXIMIDAMIDE; Debrisoquin sulphate; DEBRISOQUIN SULFATE; Isocaramidine; Debrisochinum; Debrisoquinum; Debrisoquine; Debrisoquina; Debrisoquin; Tendor; Debrisoquin; Debrisoquine



数据库引用编号

19 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(5)

BioCyc(0)

PlantCyc(0)

代谢反应

66 个相关的代谢反应过程信息。

Reactome(65)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(1)

PathBank(0)

PharmGKB(0)

11 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表
Cytoplasm 14 ABCB1, ALB, AXIN2, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, GSTM1, HPGDS, NAT2, WDR20
Peripheral membrane protein 2 CYP2B6, CYP2E1
Endoplasmic reticulum membrane 8 CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4
Nucleus 5 ALB, AXIN2, NAT2, VEZF1, WDR20
cytosol 6 ALB, AXIN2, COMT, GSTM1, HPGDS, NAT2
dendrite 1 COMT
centrosome 2 ALB, AXIN2
nucleoplasm 3 HPGDS, VEZF1, WDR20
Cell membrane 3 ABCB1, COMT, NAT2
Multi-pass membrane protein 3 ABCB1, CACNA1I, NAT2
Synapse 1 COMT
cell surface 1 ABCB1
Golgi apparatus 1 ALB
Golgi membrane 1 INS
mitochondrial inner membrane 1 CYP2E1
neuronal cell body 1 NAT2
plasma membrane 8 ABCB1, AXIN2, CACNA1I, COMT, CYP2C19, CYP2C9, NAT2, REN
Membrane 8 ABCB1, CACNA1I, COMT, CYP2A6, CYP2D6, CYP3A4, NAT2, REN
apical plasma membrane 1 ABCB1
axon 2 COMT, NAT2
basolateral plasma membrane 1 NAT2
extracellular exosome 4 ABCB1, ALB, COMT, NAT2
endoplasmic reticulum 2 ALB, CYP2D6
extracellular space 3 ALB, INS, REN
mitochondrion 1 CYP2D6
protein-containing complex 1 ALB
intracellular membrane-bounded organelle 10 COMT, CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4, HPGDS
Microsome membrane 6 CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, CYP3A4
Secreted 3 ALB, INS, REN
extracellular region 3 ALB, INS, REN
Single-pass membrane protein 1 CYP2D6
Extracellular side 1 COMT
anchoring junction 1 ALB
transcription regulator complex 1 NAT2
beta-catenin destruction complex 1 AXIN2
apical part of cell 1 REN
Single-pass type II membrane protein 1 COMT
Apical cell membrane 1 ABCB1
Mitochondrion inner membrane 1 CYP2E1
ciliary basal body 1 ALB
centriole 1 ALB
spindle pole 1 ALB
blood microparticle 1 ALB
intercellular bridge 1 GSTM1
endosome lumen 1 INS
secretory granule lumen 1 INS
Golgi lumen 1 INS
endoplasmic reticulum lumen 2 ALB, INS
platelet alpha granule lumen 1 ALB
voltage-gated calcium channel complex 1 CACNA1I
transport vesicle 1 INS
Endoplasmic reticulum-Golgi intermediate compartment membrane 1 INS
cytoplasmic microtubule 1 CYP2A6
external side of apical plasma membrane 2 ABCB1, NAT2
[Isoform Soluble]: Cytoplasm 1 COMT
[Isoform Membrane-bound]: Cell membrane 1 COMT
NatA complex 1 NAT2
ciliary transition fiber 1 ALB


文献列表

  • Carley R Corado, Daniel S McKemie, Heather K Knych. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds. American journal of veterinary research. 2016 Sep; 77(9):1029-35. doi: 10.2460/ajvr.77.9.1029. [PMID: 27580115]
  • Colin J Henderson, Lesley A McLaughlin, Nico Scheer, Lesley A Stanley, C Roland Wolf. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo. Molecular pharmacology. 2015 Apr; 87(4):733-9. doi: 10.1124/mol.114.097394. [PMID: 25657337]
  • Ran-Ran Zhang, Yun-Wen Zheng, Bin Li, Tomonori Tsuchida, Yasuharu Ueno, Yun-Zhong Nie, Hideki Taniguchi. Human hepatic stem cells transplanted into a fulminant hepatic failure Alb-TRECK/SCID mouse model exhibit liver reconstitution and drug metabolism capabilities. Stem cell research & therapy. 2015 Mar; 6(?):49. doi: 10.1186/s13287-015-0038-9. [PMID: 25889844]
  • Markéta Paloncýová, Karel Berka, Michal Otyepka. Molecular insight into affinities of drugs and their metabolites to lipid bilayers. The journal of physical chemistry. B. 2013 Feb; 117(8):2403-10. doi: 10.1021/jp311802x. [PMID: 23387302]
  • Daniel J Warner, Hongming Chen, Louis-David Cantin, J Gerry Kenna, Simone Stahl, Clare L Walker, Tobias Noeske. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals. 2012 Dec; 40(12):2332-41. doi: 10.1124/dmd.112.047068. [PMID: 22961681]
  • A Helldén, G Panagiotidis, P Johansson, N Waters, S Waters, J Tedroff, L Bertilsson. The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans. European journal of clinical pharmacology. 2012 Sep; 68(9):1281-6. doi: 10.1007/s00228-012-1248-z. [PMID: 22399238]
  • Sui-Lin Mo, Wei-Feng Liu, Chun-Guang Li, Zhi-Wei Zhou, Hai-Bin Luo, Helen Chew, Jun Liang, Shu-Feng Zhou. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. Current pharmaceutical biotechnology. 2012 Jul; 13(9):1640-704. doi: 10.2174/138920112800958779. [PMID: 22039821]
  • Stephen J Fey, Krzysztof Wrzesinski. Determination of drug toxicity using 3D spheroids constructed from an immortal human hepatocyte cell line. Toxicological sciences : an official journal of the Society of Toxicology. 2012 Jun; 127(2):403-11. doi: 10.1093/toxsci/kfs122. [PMID: 22454432]
  • Hua Cai, Jun Jiang, Qi Yang, Qingmei Chen, Yiqun Deng. Functional characterization of a first avian cytochrome P450 of the CYP2D subfamily (CYP2D49). PloS one. 2012; 7(6):e38395. doi: 10.1371/journal.pone.0038395. [PMID: 22675558]
  • Trine Naalsund Andreassen, Ingrid Eftedal, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. European journal of clinical pharmacology. 2012 Jan; 68(1):55-64. doi: 10.1007/s00228-011-1093-5. [PMID: 21735164]
  • Junichi Azuma, Tomoko Hasunuma, Masanori Kubo, Masaya Miyatake, Toshiko Koue, Koushi Higashi, Tsutomu Fujiwara, Sachiko Kitahara, Tamiki Katano, Sumiko Hara. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. European journal of clinical pharmacology. 2012 Jan; 68(1):29-37. doi: 10.1007/s00228-011-1094-4. [PMID: 21739267]
  • Trine Naalsund Andreassen, Pål Klepstad, Andrew Davies, Kristin Bjordal, Staffan Lundström, Stein Kaasa, Ola Dale. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. European journal of clinical pharmacology. 2011 May; 67(5):493-506. doi: 10.1007/s00228-010-0948-5. [PMID: 21140139]
  • Nicolas A Stewart, Shama C Buch, Thomas P Conrads, Robert A Branch. A UPLC-MS/MS assay of the "Pittsburgh cocktail": six CYP probe-drug/metabolites from human plasma and urine using stable isotope dilution. The Analyst. 2011 Feb; 136(3):605-12. doi: 10.1039/c0an00643b. [PMID: 21107456]
  • Offie P Soldin, Sarah H Chung, Donald R Mattison. Sex differences in drug disposition. Journal of biomedicine & biotechnology. 2011; 2011(?):187103. doi: 10.1155/2011/187103. [PMID: 21403873]
  • Stefano Zamuner, Brendan M Johnson, Sabrina Pagliarusco, Paolo Fina, Michela Peroni, Monica Fiore, Laurel M Adams, Sofia A Fernandes. Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British journal of clinical pharmacology. 2010 Oct; 70(4):537-46. doi: 10.1111/j.1365-2125.2010.03729.x. [PMID: 20840445]
  • Evagelia C Laiakis, Gerard A J Morris, Albert J Fornace, Stephen R C Howie. Metabolomic analysis in severe childhood pneumonia in the Gambia, West Africa: findings from a pilot study. PloS one. 2010 Sep; 5(9):. doi: 10.1371/journal.pone.0012655. [PMID: 20844590]
  • Eszter Kirilly. Long-term neuronal damage and recovery after a single dose of MDMA: expression and distribution of serotonin transporter in the rat brain. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology. 2010 Sep; 12(3):413-23. doi: . [PMID: 20962361]
  • Stjepan Pepeljnjak, Maja Šegvić Klarić. «Suspects» in etiology of endemic nephropathy: aristolochic acid versus mycotoxins. Toxins. 2010 06; 2(6):1414-27. doi: 10.3390/toxins2061414. [PMID: 22069645]
  • Hidetaka Kamimura, Naoyuki Nakada, Katsuhiro Suzuki, Ayako Mera, Kinya Souda, Yuichi Murakami, Kohichiro Tanaka, Takafumi Iwatsubo, Akio Kawamura, Takashi Usui. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug metabolism and pharmacokinetics. 2010; 25(3):223-35. doi: 10.2133/dmpk.25.223. [PMID: 20610881]
  • Takashi Ito, Motohiro Kato, Koji Chiba, Osamu Okazaki, Yuichi Sugiyama. Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature. Drug metabolism and pharmacokinetics. 2010; 25(3):243-53. doi: 10.2133/dmpk.25.243. [PMID: 20610883]
  • Markus P Schlaich, Flora Socratous, Sarah Hennebry, Nina Eikelis, Elisabeth A Lambert, Nora Straznicky, Murray D Esler, Gavin W Lambert. Sympathetic activation in chronic renal failure. Journal of the American Society of Nephrology : JASN. 2009 May; 20(5):933-9. doi: 10.1681/asn.2008040402. [PMID: 18799718]
  • Kevin M O'Shaughnessy. Dissecting complex traits: recent advances in hypertension genomics. Genome medicine. 2009 Apr; 1(4):43. doi: 10.1186/gm43. [PMID: 19439027]
  • Angelo A Izzo, Edzard Ernst. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009; 69(13):1777-98. doi: 10.2165/11317010-000000000-00000. [PMID: 19719333]
  • Susanne Löfgren, Stina Ekman, Ylva Terelius, Ronny Fransson-Steen. Few alterations in clinical pathology and histopathology observed in a CYP2C18&19 humanized mice model. Acta veterinaria Scandinavica. 2008 Nov; 50(?):47. doi: 10.1186/1751-0147-50-47. [PMID: 19038035]
  • Bill J Gurley, Ashley Swain, Martha A Hubbard, D Keith Williams, Gary Barone, Faith Hartsfield, Yudong Tong, Danielle J Carrier, Shreekar Cheboyina, Sunil K Battu. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Molecular nutrition & food research. 2008 Jul; 52(7):755-63. doi: 10.1002/mnfr.200600300. [PMID: 18214849]
  • Roger J Sullivan, Edward H Hagen, Peter Hammerstein. Revealing the paradox of drug reward in human evolution. Proceedings. Biological sciences. 2008 Jun; 275(1640):1231-41. doi: 10.1098/rspb.2007.1673. [PMID: 18353749]
  • Silvana Penco, Massimo Buscema, Maria Cristina Patrosso, Alessandro Marocchi, Enzo Grossi. New application of intelligent agents in sporadic amyotrophic lateral sclerosis identifies unexpected specific genetic background. BMC bioinformatics. 2008 May; 9(?):254. doi: 10.1186/1471-2105-9-254. [PMID: 18513389]
  • Miki Katoh, Chise Tateno, Katsutoshi Yoshizato, Tsuyoshi Yokoi. Chimeric mice with humanized liver. Toxicology. 2008 Apr; 246(1):9-17. doi: 10.1016/j.tox.2007.11.012. [PMID: 18248870]
  • Jeroen Wink, Bernadette Th Veering, Michel Kruit, Anton G L Burm, Gunilla A I Huledal, Gunilla Y Ekström, Rudolf Stienstra, Jack W van Kleef. The effect of a long term epidural infusion of ropivacaine on CYP2D6 activity. Anesthesia and analgesia. 2008 Jan; 106(1):143-6, table of contents. doi: 10.1213/01.ane.0000297293.84075.74. [PMID: 18165569]
  • L Bertilsson. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clinical pharmacology and therapeutics. 2007 Nov; 82(5):606-9. doi: 10.1038/sj.clpt.6100358. [PMID: 17898711]
  • Idilio González, Bárbaro Pérez, Mayra Alvarez, Pedro Dorado, Adrián Llerena. [Study of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards]. Medicina clinica. 2007 May; 128(20):772-4. doi: 10.1157/13106328. [PMID: 17568504]
  • Pedro Dorado, Roland Berecz, Eva M Peñas-Lledó, Alfredo de la Rubia, Adrián Llerena. No effect of the CYP1A2*1F genotype on thioridazine, mesoridazine, sulforidazine plasma concentrations in psychiatric patients. European journal of clinical pharmacology. 2007 May; 63(5):527-8. doi: 10.1007/s00228-007-0284-6. [PMID: 17345072]
  • D Frank, U Jaehde, U Fuhr. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. European journal of clinical pharmacology. 2007 Apr; 63(4):321-33. doi: 10.1007/s00228-006-0250-8. [PMID: 17273835]
  • U Fuhr, A Jetter, J Kirchheiner. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clinical pharmacology and therapeutics. 2007 Feb; 81(2):270-83. doi: 10.1038/sj.clpt.6100050. [PMID: 17259951]
  • Reginald F Frye, Nathalie K Zgheib, Gary R Matzke, Diego Chaves-Gnecco, Mordechai Rabinovitz, Obaid S Shaikh, Robert A Branch. Liver disease selectively modulates cytochrome P450--mediated metabolism. Clinical pharmacology and therapeutics. 2006 Sep; 80(3):235-45. doi: 10.1016/j.clpt.2006.05.006. [PMID: 16952490]
  • Yueying Zhen, Ondrej Slanar, Kristopher W Krausz, Chi Chen, Josef Slavík, Kerry L McPhail, T Mark Zabriskie, Frantisek Perlík, Frank J Gonzalez, Jeffrey R Idle. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Drug metabolism and disposition: the biological fate of chemicals. 2006 Sep; 34(9):1563-74. doi: 10.1124/dmd.105.008920. [PMID: 16782768]
  • Nathalie K Zgheib, Reginald F Frye, Timothy S Tracy, Marjorie Romkes, Robert A Branch. Validation of incorporating flurbiprofen into the Pittsburgh cocktail. Clinical pharmacology and therapeutics. 2006 Sep; 80(3):257-63. doi: 10.1016/j.clpt.2006.06.005. [PMID: 16952492]
  • Greer M Murphy. Application of microarray technology in psychotropic drug trials. Journal of psychopharmacology (Oxford, England). 2006 Jul; 20(4 Suppl):72-8. doi: 10.1177/1359786806066059. [PMID: 16785274]
  • Agneta Wennerholm, Anna Nordmark, Maria Pihlsgård, Margarita Mahindi, Leif Bertilsson, Lars L Gustafsson. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European journal of clinical pharmacology. 2006 Jul; 62(7):539-46. doi: 10.1007/s00228-006-0121-3. [PMID: 16783563]
  • Paula Macedo Cerqueira, Eduardo Barbosa Coelho, Tufik José Magalhães Geleilete, Gustavo Henrique Goldman, Vera Lucia Lanchote. Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. Journal of clinical pharmacology. 2005 Dec; 45(12):1422-33. doi: 10.1177/0091270005281816. [PMID: 16291718]
  • Curtis E Haas, Daniel Brazeau, Denise Cloen, Brent M Booker, Valerie Frerichs, Colleen Zaranek, Reginald F Frye, Thomas Kufel. Cytochrome P450 mRNA expression in peripheral blood lymphocytes as a predictor of enzyme induction. European journal of clinical pharmacology. 2005 Sep; 61(8):583-93. doi: 10.1007/s00228-005-0971-0. [PMID: 16041547]
  • Bill J Gurley, Stephanie F Gardner, Martha A Hubbard, D Keith Williams, W Brooks Gentry, Ikhlas A Khan, Amit Shah. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clinical pharmacology and therapeutics. 2005 May; 77(5):415-26. doi: 10.1016/j.clpt.2005.01.009. [PMID: 15900287]
  • Pedro Dorado, Roland Berecz, Macarena C Cáceres, Idilio González, Jesús Cobaleda, Adrián Llerena. Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clinical chemistry and laboratory medicine. 2005; 43(3):275-9. doi: 10.1515/cclm.2005.046. [PMID: 15843230]
  • Pierre Baumann, Sven Ulrich, Gabriel Eckermann, Manfred Gerlach, Hans-Joachim Kuss, Gerd Laux, Bruno Müller-Oerlinghausen, Marie Luise Rao, Peter Riederer, Gerald Zernig, Christoph Hiemke. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues in clinical neuroscience. 2005; 7(3):231-47. doi: NULL. [PMID: 16156382]
  • Bill J Gurley, Stephanie F Gardner, Martha A Hubbard, D Keith Williams, W Brooks Gentry, Yanyan Cui, Catharina Y W Ang. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs & aging. 2005; 22(6):525-39. doi: 10.2165/00002512-200522060-00006. [PMID: 15974642]
  • Zourab Bebia, Shama C Buch, John W Wilson, Reginald F Frye, Marjorie Romkes, Alfred Cecchetti, Diego Chaves-Gnecco, Robert A Branch. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clinical pharmacology and therapeutics. 2004 Dec; 76(6):618-27. doi: 10.1016/j.clpt.2004.08.021. [PMID: 15592333]
  • Mahmut Ozdemir, Kim H Crewe, Geoffrey T Tucker, Amin Rostami-Hodjegan. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. Journal of clinical pharmacology. 2004 Dec; 44(12):1398-404. doi: 10.1177/0091270004269582. [PMID: 15545311]
  • Monika Szewczuk-Bogusławska, Magdalena Grzesiak, Jan Aleksander Beszłej, Andrzej Kiejna. [Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]. Psychiatria polska. 2004 Nov; 38(6):1093-104. doi: . [PMID: 15779673]
  • Bill J Gurley, Stephanie F Gardner, Martha A Hubbard, D Keith Williams, W Brooks Gentry, Julie Carrier, Ikhlas A Khan, David J Edwards, Amit Shah. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clinical pharmacology and therapeutics. 2004 Nov; 76(5):428-40. doi: 10.1016/j.clpt.2004.07.007. [PMID: 15536458]
  • Soo-Youn Lee, Chang-Seok Ki, Kyung Sue Hong, Jong Won Kim. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication. Journal of Korean medical science. 2004 Oct; 19(5):750-2. doi: 10.3346/jkms.2004.19.5.750. [PMID: 15483356]
  • R Berecz, P Dorado, A De La Rubia, M C Cáceres, I Degrell, A LLerena. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions. Current drug targets. 2004 Aug; 5(6):573-9. doi: 10.2174/1389450043345263. [PMID: 15270204]
  • Adrián LLerena, Alfredo de la Rubia, Roland Berecz, Pedro Dorado. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. Pharmacopsychiatry. 2004 Mar; 37(2):69-73. doi: 10.1055/s-2004-815528. [PMID: 15048614]
  • G E Blakey, J A Lockton, J Perrett, P Norwood, M Russell, Z Aherne, J Plume. Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1. British journal of clinical pharmacology. 2004 Feb; 57(2):162-9. doi: 10.1046/j.1365-2125.2003.01973.x. [PMID: 14748815]
  • Ophelia Q P Yin, Sherry S L Lam, Cindy M Y Lo, Moses S S Chow. Rapid determination of five probe drugs and their metabolites in human plasma and urine by liquid chromatography/tandem mass spectrometry: application to cytochrome P450 phenotyping studies. Rapid communications in mass spectrometry : RCM. 2004; 18(23):2921-33. doi: 10.1002/rcm.1704. [PMID: 15529418]
  • Karin Herrlin, Norio Yasui-Furukori, Gunnel Tybring, Jolanta Widén, Lars L Gustafsson, Leif Bertilsson. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. British journal of clinical pharmacology. 2003 Oct; 56(4):415-21. doi: 10.1046/j.1365-2125.2003.01874.x. [PMID: 12968986]
  • Conny Nordin, Marja Liisa Dahl, Thomas Eklundh, Mats Eriksson, Stefan Sjöberg. CSF taurine level is influenced by plasma cholesterol and the CYP2D6 phenotype. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2003 Oct; 13(5):333-5. doi: 10.1016/s0924-977x(03)00033-6. [PMID: 12957331]
  • Jonatan D Lindh, Anita Annas, Lennart Meurling, Marja-Liisa Dahl, Ayman AL-Shurbaji. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. European journal of clinical pharmacology. 2003 Sep; 59(5-6):401-6. doi: 10.1007/s00228-003-0627-x. [PMID: 12898080]
  • Magnus Christensen, Katarina Andersson, Per Dalén, Rajaa A Mirghani, Gary J Muirhead, Anna Nordmark, Gunnel Tybring, Anneli Wahlberg, Umit Yaşar, Leif Bertilsson. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clinical pharmacology and therapeutics. 2003 Jun; 73(6):517-28. doi: 10.1016/s0009-9236(03)00050-x. [PMID: 12811361]
  • P Dalén, M-L Dahl, H-K Roh, G Tybring, M Eichelbaum, G R Wilkinson, L Bertilsson. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians. British journal of clinical pharmacology. 2003 Jun; 55(6):630-4. doi: 10.1046/j.1365-2125.2003.01804.x. [PMID: 12814461]
  • Paula Macedo Cerqueira, Evandro José Cesarino, Carlo Bertucci, Pierina Sueli Bonato, Vera Lucia Lanchote. Stereoselective metabolism of metoprolol: enantioselectivity of alpha-hydroxymetoprolol in plasma and urine. Chirality. 2003 Jun; 15(6):542-9. doi: 10.1002/chir.10244. [PMID: 12774293]
  • Rajaa A Mirghani, Orjan Ericsson, Gunnel Tybring, Lars L Gustafsson, Leif Bertilsson. Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. European journal of clinical pharmacology. 2003 May; 59(1):23-8. doi: 10.1007/s00228-003-0575-5. [PMID: 12743670]
  • Roland Berecz, Alfredo de la Rubia, Pedro Dorado, Pedro Fernández-Salguero, Marja-Liisa Dahl, Adrián LLerena. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. European journal of clinical pharmacology. 2003 May; 59(1):45-50. doi: 10.1007/s00228-003-0576-4. [PMID: 12682803]
  • Juan Antonio Carrillo, Angustias G Herráiz, Sara Isabel Ramos, Guillermo Gervasini, Sonia Vizcaíno, Julio Benítez. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. Journal of clinical psychopharmacology. 2003 Apr; 23(2):119-27. doi: 10.1097/00004714-200304000-00003. [PMID: 12640212]
  • Bang Qian Xu, Mikio Ishii, Li Rong Ding, Nancy E Fischer, Tadanobu Inaba. Interaction of serum proteins with CYP isoforms in human liver microsomes: inhibitory effects of human and bovine albumin, alpha-globulins, alpha-1-acid glycoproteins and gamma-globulins on CYP2C19 and CYP2D6. Life sciences. 2003 Mar; 72(17):1953-62. doi: 10.1016/s0024-3205(03)00093-6. [PMID: 12597994]
  • Stephan A Chalon, Jean-Pierre Desager, Karl A Desante, Reginald F Frye, Jennifer Witcher, Amanda J Long, John-Michael Sauer, Jean-Luc Golnez, Brian P Smith, Holly R Thomasson, Yves Horsmans. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clinical pharmacology and therapeutics. 2003 Mar; 73(3):178-91. doi: 10.1067/mcp.2003.25. [PMID: 12621383]
  • Paula Macedo Cerqueira, Vanessa Bergamin Boralli, Eduardo Barbosa Coelho, Norberto Peporine Lopes, Luis Fernando Lopes Guimarães, Pierina Sueli Bonato, Vera Lucia Lanchote. Enantioselective determination of metoprolol acidic metabolite in plasma and urine using liquid chromatography chiral columns: applications to pharmacokinetics. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2003 Jan; 783(2):433-41. doi: 10.1016/s1570-0232(02)00705-5. [PMID: 12482486]
  • Adrián LLerena, Roland Berecz, Alfredo de la Rubia, Pedro Dorado. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. Journal of psychopharmacology (Oxford, England). 2002 Dec; 16(4):361-4. doi: 10.1177/026988110201600411. [PMID: 12503836]
  • J L C M Dorne, K Walton, W Slob, A G Renwick. Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate?. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 2002 Nov; 40(11):1633-56. doi: 10.1016/s0278-6915(02)00117-5. [PMID: 12176090]
  • R Berecz, A LLerena, A de la Rubia, J Gómez, M Kellermann, P Dorado, I Degrell. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry. 2002 Nov; 35(6):231-4. doi: 10.1055/s-2002-36389. [PMID: 12518271]
  • LalithKumar K Solai, Bruce G Pollock, Benoit H Mulsant, Reginald F Frye, Mark D Miller, Robert A Sweet, Maggie Kirshner, Denise Sorisio, Amy Begley, Charles F Reynolds. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. Journal of clinical psychopharmacology. 2002 Oct; 22(5):481-6. doi: 10.1097/00004714-200210000-00007. [PMID: 12352271]
  • Bill J Gurley, Stephanie F Gardner, Martha A Hubbard, D Keith Williams, W Brooks Gentry, Yanyan Cui, Catharina Y W Ang. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clinical pharmacology and therapeutics. 2002 Sep; 72(3):276-87. doi: 10.1067/mcp.2002.126913. [PMID: 12235448]
  • Selim Kortunay, Atila Bozkurt, Nursabah E Basci, S Oguz Kayaalp. Effects of terfenadine and diphenhydramine on the CYP2D6 activity in healthy volunteers. European journal of drug metabolism and pharmacokinetics. 2002 Jul; 27(3):171-4. doi: 10.1007/bf03190453. [PMID: 12365197]
  • Adrián LLerena, Roland Berecz, Alfredo de la Rubia, Pedro Dorado. QTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy. European journal of clinical pharmacology. 2002 Jun; 58(3):223-24. doi: 10.1007/s00228-002-0452-7. [PMID: 12162273]
  • Magnus Christensen, Gunnel Tybring, Kazuo Mihara, Norio Yasui-Furokori, Juan Antonio Carrillo, Sara I Ramos, Katarina Andersson, Marja-Liisa Dahl, Leif Bertilsson. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clinical pharmacology and therapeutics. 2002 Mar; 71(3):141-52. doi: 10.1067/mcp.2002.121788. [PMID: 11907488]
  • Susanne Ammon, Claudia Marx, Christoph Behrens, Ute Hofmann, Thomas Mürdter, Ernst-Ulrich Griese, Gerd Mikus. Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers. BMC clinical pharmacology. 2002 Feb; 2(?):2. doi: 10.1186/1472-6904-2-2. [PMID: 11943073]
  • Reginald F Frye, Robert A Branch. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. British journal of clinical pharmacology. 2002 Feb; 53(2):155-62. doi: 10.1046/j.1365-2125.2002.01522.x. [PMID: 11851639]
  • Ayman Al-Shurbaji, Juliette Säwe. The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype. European journal of clinical pharmacology. 2002 Feb; 57(12):877-81. doi: 10.1007/s00228-001-0413-6. [PMID: 11936707]
  • A LLerena, R Berecz, A de la Rubia, P Fernández-Salguero, P Dorado. Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Therapeutic drug monitoring. 2001 Dec; 23(6):616-20. doi: 10.1097/00007691-200112000-00004. [PMID: 11802093]
  • J Corchero, C P Granvil, T E Akiyama, G P Hayhurst, S Pimprale, L Feigenbaum, J R Idle, F J Gonzalez. The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Molecular pharmacology. 2001 Dec; 60(6):1260-7. doi: 10.1124/mol.60.6.1260. [PMID: 11723233]
  • G M Murphy, B G Pollock, M A Kirshner, N Pascoe, W Cheuk, B H Mulsant, C F Reynolds. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2001 Nov; 25(5):737-43. doi: 10.1016/s0893-133x(01)00289-5. [PMID: 11682257]
  • J L Palmer, R J Scott, A Gibson, M Dickins, S Pleasance. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). British journal of clinical pharmacology. 2001 Nov; 52(5):555-61. doi: 10.1046/j.0306-5251.2001.01479.x. [PMID: 11736864]
  • K Laine, G Tybring, S Härtter, K Andersson, J O Svensson, J Widén, L Bertilsson. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clinical pharmacology and therapeutics. 2001 Oct; 70(4):327-35. doi: . [PMID: 11673748]
  • M Ishii, B Q Xu, L R Ding, N E Fischer, T Inaba. Interaction of plasma proteins with cytochromes P450 mediated metabolic reactions: inhibition by human serum albumin and alpha-globulins of the debrisoquine 4-hydroxylation (CYP2D) in liver microsomes of human, hamster and rat. Toxicology letters. 2001 Mar; 119(3):219-25. doi: 10.1016/s0378-4274(01)00264-8. [PMID: 11246175]
  • B Olsson, N Brynne, C Johansson, H Arnberg. Food increases the bioavailability of tolterodine but not effective exposure. Journal of clinical pharmacology. 2001 Mar; 41(3):298-304. doi: 10.1177/00912700122010113. [PMID: 11269570]
  • S Murray, A O Odupitan, B P Murray, A R Boobis, R J Edwards. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Xenobiotica; the fate of foreign compounds in biological systems. 2001 Mar; 31(3):135-51. doi: 10.1080/00498250110043292. [PMID: 11465391]
  • M M Shi, S P Myrand, M R Bleavins, F A de la Iglesia. Genotyping for Functionally Important Human CYP2D6*4 (B) Mutation Using TaqMan Probes. Methods in molecular medicine. 2001; 49(?):459-72. doi: 10.1385/1-59259-081-0:459. [PMID: 21370161]
  • P M Cerqueira, F H Mateus, E J Cesarino, P S Bonato, V L Lanchote. Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers. Journal of chromatography. B, Biomedical sciences and applications. 2000 Dec; 749(2):153-61. doi: 10.1016/s0378-4347(00)00402-3. [PMID: 11145052]
  • M Radziwoń-Zaleska, H Matsumoto, M Skalski, W Androsiuk, A Dziklińska, P K Kunicki. Therapeutic drug monitoring in depression. Polish journal of pharmacology. 2000 Jul; 52(4):255-66. doi: NULL. [PMID: 11345481]
  • E Haffen, G Paintaud, M Berard, C Masuyer, Y Bechtel, P R Bechtel. On the assessment of drug metabolism by assays of codeine and its main metabolites. Therapeutic drug monitoring. 2000 Jun; 22(3):258-65. doi: 10.1097/00007691-200006000-00005. [PMID: 10850391]
  • V A Pereira, J O Auler, M J Carmona, F H Mateus, V L Lanchote, D D Breimer, S R Santos. A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. 2000 May; 33(5):509-14. doi: 10.1590/s0100-879x2000000500004. [PMID: 10775881]
  • P Dalén, M Dahl, K Andersson, L Bertilsson. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes. British journal of clinical pharmacology. 2000 Feb; 49(2):180-4. doi: 10.1046/j.1365-2125.2000.00120.x. [PMID: 10671914]
  • T E Heiskanen, P M Ruismäki, T A Seppälä, E A Kalso. Morphine or oxycodone in cancer pain?. Acta oncologica (Stockholm, Sweden). 2000; 39(8):941-7. doi: 10.1080/02841860050215927. [PMID: 11207001]
  • P Dalén, M L Dahl, M Eichelbaum, L Bertilsson, G R Wilkinson. Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics. 1999 Dec; 9(6):697-706. doi: 10.1097/01213011-199912000-00004. [PMID: 10634132]
  • J O Svensson, L Bertilsson. Rapid high-performance liquid chromatographic method for determination of debrisoquine and 4-hydroxy-debrisoquine in urine for CYP2D6 phenotyping. Pharmacogenetics. 1999 Aug; 9(4):529-31. doi: NULL. [PMID: 10780273]
  • Y Caraco, J Sheller, A J Wood. Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects. The Journal of pharmacology and experimental therapeutics. 1999 Jul; 290(1):413-22. doi: NULL. [PMID: 10381807]
  • P Sandwall, M W Lo, B Jonzon, P Dalén, C Furtek, M Ritter, G Alván, J McCrea, F Sjöqvist. Lack of polymorphism of the conversion of losartan to its active metabolite E-3174 in extensive and poor metabolizers of debrisoquine (cytochrome P450 2D6) and mephenytoin (cytochrome P450 2C19). European journal of clinical pharmacology. 1999 Jun; 55(4):279-83. doi: 10.1007/s002280050629. [PMID: 10424320]
  • S Kortunay, A Bozkurt, L Bathum, N E Basci, M Calgüneri, K Brøsen, S O Kayaalp. CYP2D6 polymorphism in systemic lupus erythematosus patients. European journal of clinical pharmacology. 1999 Mar; 55(1):21-5. doi: 10.1007/s002280050587. [PMID: 10206080]
  • N Brynne, Y Böttiger, B Hallén, L Bertilsson. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. British journal of clinical pharmacology. 1999 Feb; 47(2):145-50. doi: 10.1046/j.1365-2125.1999.00865.x. [PMID: 10190648]
  • P M Cerqueira, E J Cesarino, F H Mateus, Y Mere, S R Santos, V L Lanchote. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality. 1999; 11(7):591-7. doi: 10.1002/(sici)1520-636x(1999)11:7<591::aid-chir12>3.0.co;2-t. [PMID: 10423287]